Childhood wheezing with rhinovirus can increase asthma risk, study indicates
02 Oct 2008

Children who experience wheezing with rhinovirus are at increased risk of developing asthma later in life, according to a new study.

Led by researchers at US academic institution the University of Wisconsin and published in the first October issue of the American Journal of Respiratory and Critical Care Medicine, the study involved almost 300 newborns deemed to be at high risk of the condition.

They were followed from birth to the age of six and were evaluated for the presence of specific viruses during wheezing illnesses.

By the time they reached their sixth year of life, 28 per cent of the children had asthma, with those who had wheezed with rhinovirus disproportionately among them, according to the study.

Those who wheezed during the first year of life were nearly three times as likely to have the condition by the time they were six, with the risk increasing to nearly six times if they wheezed with the virus during their second year.

"We have found that rhinovirus - the most common cause of colds - contributes a disproportionate amount towards future asthma development in comparison to other viruses that also cause childhood wheezing," commented lead investigator Dr Robert Lemanske Jr.

Login and visit the Asthma Knowledge Centre

Print Article    Bookmark

• Study looks at pros and cons of combined asthma treatment 11/12/08
• Caesarean section babies more prone to asthma, says study 02/12/08
• Study links season of birth to asthma risk 24/11/08
• Autumn babies linked with higher asthma risk 21/11/08
• Traffic pollution worsens child asthma symptoms, study finds 14/11/08

• DUOVENT - 50.64%
  Duovent and Duovent Autohaler: Treatment of reversible airways obstruction, as in bronchial asthma, bronchitis and emphysema. Duovent UDV: Acute severe asthma Duovent UDV: Acute severe asthma or acute exacerbation of chronic asthma presenting as an emergency requiring treatment by nebuliser ...
  
  
• PHYLLOCONTIN CONTINUS PAEDIATRIC - 49.42%
  Bronchospasm associated with asthma, COPD and chronic bronchitis. Pulmicort Turbohaler, Pulmicort Inhaler and Pulmicort L.S.: Bronchial asthma. Pulmicort Respules: Bronchial asthma in patients where MDIs or breath-actuated inhalers are inadequate. Croup ...
  
  
• FLIXOTIDE - 49.42%
  Diskhaler, Inhaler, Evohaler and Accuhaler: Prophylaxis of bronchial asthma. Nebules: Both strengths, prophylactic management of severe chronic asthma in adults and children over 16 years; Lower strength only (0.5mg/2mL), treatment of acute exacerbations of asthma in children aged four to 16 years ...
  
  
• SERETIDE ACCUHALER - 48.68%
  Asthma - Seretide is indicated in the regular treatment of asthma where use of a combination product(long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist or ...
  
  
• THEO-DUR - 48.68%
  Bronchospasm associated with asthma and chronic bronchitis. Nocturnal asthma. Nocturnal asthma ...
  
  
• SYMBICORT 100/6 TURBOHALER - 47.95%
  Symbicort Turbohaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.or - patients ...